News
IONS
56.55
+1.22%
0.68
Morgan Stanley Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
TipRanks · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Arrowhead Pharmaceuticals (ARWR) and Insight Molecular Diagnostics (IMDX)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Ionis Pharmaceuticals (IONS) and Repligen (RGEN)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Claritev (CTEV), Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR)
TipRanks · 1d ago
Ionis Buy Rating Reaffirmed as TRYNGOLZA Lead and Competitive Edge Support Unchanged $125 Price Target
TipRanks · 1d ago
Ionis Pharmaceuticals (IONS) Gets a Buy from Barclays
TipRanks · 1d ago
Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential
Seeking Alpha · 2d ago
Arrowhead hits 52-week high as late-stage trial win marks “derisking event”
Seeking Alpha · 2d ago
Ionis Maintains Buy Rating as Olezarsen’s sHTG Profile Outshines Rival; $86 Price Target Reaffirmed
TipRanks · 2d ago
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials
Seeking Alpha · 2d ago
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug
Seeking Alpha · 2d ago
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease
Seeking Alpha · 2d ago
Does Eplontersen’s Phase 3 Miss and Dravet Progress Change The Bull Case For Ionis (IONS)?
Simply Wall St · 3d ago
Tracking Baker Brothers Portfolio: Q1 2026 Update
Seeking Alpha · 3d ago
Ionis Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones · 3d ago
Ionis Pharmaceuticals Price Target Cut to $89.00/Share From $106.00 by Guggenheim
Dow Jones · 3d ago
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $89
Benzinga · 3d ago
These healthcare stocks are trading near oversold levels as earnings season picks up
Seeking Alpha · 3d ago
IONIS PHARMACEUTICALS INC <IONS.O>: GUGGENHEIM CUTS TARGET PRICE TO $89 FROM $106
Reuters · 3d ago
Cathie Wood’s ARK Invest adds another $57M to SpaceX, sells $39M stake in AMD
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.